Update on HIV/HCV Coinfection

详细信息    查看全文

• 作者：Vincent Soriano (1)
  Eugenia Vispo (1)
  Jose Vicente Fernandez-Montero (1)
  Pablo Labarga (1)
  Pablo Barreiro (1)
  
• 关键词：Hepatitis C ; HIV ; Coinfection ; HIV/HCV coinfection ; Sofosbuvir ; Telaprevir ; Boceprevir ; Antiviral therapy
• 刊名：Current HIV/AIDS Reports
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：10
• 期：3
• 页码：226-234
• 全文大小：220KB
• 参考文献：1. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med. 2006;166:1632鈥?1. CrossRef
  2. Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SHCS, 2005 to 2009. 18th CROI, Boston, MA. Feb 27-March 2, 2011. [Abstract 789].
  3. Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis. 2012;32:103鈥?3. CrossRef
  4. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073鈥?9. CrossRef
  5. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61 Suppl 1:47鈥?8. CrossRef
  6. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis. 2012;32:138鈥?6. CrossRef
  7. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128鈥?3. CrossRef
  8. Grint D, Peters L, Reekie J, et al. Stability of HCV RNA levels among interferon-na茂ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. (in press).
  9. Rockstroh J, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. (In press).
  10. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74鈥?0. CrossRef
  11. Soriano V, Puoti M, Garc铆a-Gasc贸 P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1鈥?3. CrossRef
  12. 鈥?Jones M, Nu帽ez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis. 2012;32:167鈥?6. / This review updates the most recent knowledge on the mechanisms of antiretroviral-associated liver injury and propose strategies for rapid recognition and proper management. CrossRef
  13. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother. 2010;65:543鈥?. CrossRef
  14. Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2012;13:127鈥?1. CrossRef
  15. Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P, Soriano V. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-HCV coinfected patients. AIDS. 2013;27:1187鈥?. CrossRef
  16. Labarga P, Soriano V, Vispo E, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670鈥?. CrossRef
  17. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. AIDS. 2011;25:2197鈥?08. CrossRef
  18. Perez-Cachafeiro S, del Amo J, Iribarren JA, et al. Decrease in serial prevalence of coinfection with HCV among HIV-infected patients in Spain, 1997鈥?006. Clin Infect Dis. 2009;48:1467鈥?0. CrossRef
  19. Ward J. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21:15鈥?.
  20. Samet J. Russia and HIV 鈥?beyond crime and punishment. Addiction. 2011;106:1883鈥?. CrossRef
  21. Javaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion-transmitted infections in Sub-Saharan Africa. Transfusion. 2010;50:433鈥?2. CrossRef
  22. Van der Helm J, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25:1083鈥?1. CrossRef
  23. Boesecke C, Rockstroh J. Acute hepatitis C in patients with HIV. Semin Liver Dis. 2012;32:130鈥?. CrossRef
  24. Witt M, Seaberg E, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis from 1984 to 2011. Clin Infect Dis. (in press).
  25. 鈥?AIDS European Treatment Network (NEAT). Acute hepatitis C in HIV-infected individuals: recommendations from the NEAT. AIDS. 2011;25:399鈥?09. / This article records the major conclusions reached by a group of European experts regarding the diagnosis and treatment of acute hepatitis C in HIV-infected persons. It particularly provides comprehensive and updated information on acute hepatitis C outbreaks among HIV-positive MSM.
  26. Sanchez-Parra C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. (in press).
  27. Deterding K, Gr眉ner N, Buggisch P, et al. Delayed vs immediate treatment for patients with acute hepatitis C: a randomized controlled noninferiority trial. Lancet Infect Dis. (in press).
  28. Webster D, Wojcikiewicz T, Keller M, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS. (In press).
  29. Marco A, Esteban JI, Sol茅 C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. (In press).
  30. Lambers F, Prins M, Thomas X, et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 2011;25:F21鈥?. CrossRef
  31. Mehta S, Genberg B, Astemborki J, et al. Limited uptake of hepatitis C treatment among injecting drug users. J Community. 2008;33:126鈥?3.
  32. Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451鈥?. CrossRef
  33. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438鈥?0. CrossRef
  34. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA. 2004;292:2839鈥?8. CrossRef
  35. Nu帽ez M, Miralles C, Berd煤n MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in the treatment of chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Human Retroviruses. 2007;23:972鈥?2. CrossRef
  36. 鈥?Grebely J, Oser M, Taylor L, Dore G. Breaking down the barriers to HCV treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:19鈥?5. / This article records the opinion of several experts about the ways to improve access to hepatitis C therapy in HIV-positive individuals, with particular attention to intravenous drug users and other marginal populations. CrossRef
  37. Poveda E, Vispo E, Barreiro P, et al. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther. 2012;17:571鈥?. CrossRef
  38. Soriano V, Garcia-Samaniego J. Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials. 2002;3:351鈥?. CrossRef
  39. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/HCV-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17:280鈥?. CrossRef
  40. Limketkai B, Mehta S, Sutcliffe C, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308:370鈥?. CrossRef
  41. Fern谩ndez-Montero JV, Barreiro P, Vispo E, Labarga P, S谩nchez-Parra C, Soriano V. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. AIDS. (in press).
  42. Soriano V, Labarga P, Ruiz-Sancho A, Garcia-Samaniego J, Barreiro P. Regression of liver fibrosis in hepatitis C virus/HIV-coinfected patients after treatment with pegylated interferon plus ribavirin. AIDS. 2006;20:2225鈥?. CrossRef
  43. Macias J, del Valle J, Rivero A, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV coinfection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother. 2010;65:2204鈥?1. CrossRef
  44. Barreiro P, Labarga P, Mart铆n-Carbonero L, et al. Sustained virological response following HCV therapy is associated with nonprogression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther. 2006;11:869鈥?7.
  45. Soriano V, Maida I, N煤帽ez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther. 2004;9:987鈥?2.
  46. Berenguer J, Alvarez-Pellicer J, Martin P, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. Hepatology. 2009;50:407鈥?3. CrossRef
  47. Berenguer J, Alvarez-Pellicer J, Carrero A, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with HIV and hepatitis C virus. J Hepatol. (In press).
  48. Labarga P, Fernandez-Montero JV, Barreiro P, et al. Changes in liver fibrosis in HIV/HCV coinfected patients following different outcomes with peginterferon plus ribavirin therapy. Clin Infect Dis. (In press).
  49. Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324鈥?4. CrossRef
  50. Soriano V, Labarga P, Fernandez-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antivir Res. 2013;97:36鈥?0. CrossRef
  51. 鈥?Lee M, Yang H, Lu S, et al. Chronic HCV infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469鈥?7. / This study represents a pivotal contribution on the long-term consequences of hepatitis C. Besides liver-related complications, it demonstrated that the rate of kidney disease, cardiovascular events, and some cancers increases in HCV carriers. Thus, as long as new more potent and safer curative drugs became available, treatment should not be restricted to those with advanced liver disease. CrossRef
  52. Peters L, Grint D, Lundgren J, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917鈥?6. CrossRef
  53. Bedimo R, Westfall A, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462鈥?.
  54. Soriano V, Labarga P, Vispo E, Fern谩ndez-Montero JV, Barreiro P. Treatment of hepatitis C in patients infected with HIV in the direct-acting antiviral era. Infect Dis Clin North Am. 2012;26:931鈥?8. CrossRef
  55. Sulkowski M. Current management of hepatitis C virus infection in patients with HIV coinfection. J Infect Dis. 2013;207(Suppl):26鈥?2. CrossRef
  56. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387鈥?02. CrossRef
  57. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Last accessed April 30, 2013.
  58. Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses. J Antimicrob Chemother. 2008;62:1鈥?. CrossRef
  59. Rein D, Smith B, Wittenborn J, et al. The cost-effectiveness of birth-control screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263鈥?0. CrossRef
  60. 鈥⑩€?U.S. Preventive Services Task Force (USPSTF). New HIV guidelines. (in press). / The USPSTF has recently acted decisively to accelerate routine HIV testing of all adults, following the steps taken for HCV by the CDC calling for one time testing of all baby boomers (born from 1945-1965), who are five times more likely than other adults to have HCV. In both HIV and HCV infections, expanding access to a simple test, used just one time, will identify more unaware infected people and get them treated with effective therapies while also dramatically reducing virus spread.
  61. Saifu H, Asch S, Goetz M, Smith J, Graber C, Schaberg D, et al. Evaluation of HIV and hepatitis C telemedicine clinics. Am J Manag Care. 2012;18:207鈥?2.
  62. Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected patients. Ann Intern Med. (in press).
  63. van Heeswijk R, Beumont M, Kauffman R, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. (in press).
  64. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HIV-HCV coinfected patients: end of treatment week 48 interim results. 47th EASL, Barcelona April 2012. [Abstract 366].
  65. Hulskotte E, Feng H, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718鈥?6. CrossRef
  66. de Kanter C, Blonk M, Colbers A, Schouwenberg B, Burger D. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013;56:300鈥?. CrossRef
  67. Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013;62:67鈥?3. CrossRef
  68. Benito JM, Sanchez-Parra C, Barreiro P, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther. (in press).
  69. Cotte L, Braun J, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated interferon-ribavirin in treatment-experienced HCV genotype 1/HIV coinfected patients: ANRS HC26 TelapreVIH study. CROI 2013, Atlanta, GA, March 3鈥? 2013. [Abstract 36].
  70. Poizot-Martin I, Bellissant E, Piroth L, et al. ANRS HC27 BocepreVIH interim analysis: high early virologic response with boceprevir鈥?鈥塸egylated interfer贸n鈥?鈥塺ibavirin in HCV/HCV coinfected patients with previous failure to pegylated interferon鈥?鈥塺ibavirin. CROI 2013, Atlanta, GA, March 3鈥?, 2013. [Abstract 37].
  71. Medrano J, Neukam K, Rallon N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2010;51:1209鈥?6. CrossRef
  72. Vispo E, Rallon N, Labarga P, Barreiro P, Benito JM, Soriano V. Different impact of IL28B polymorphisms on response to peginterferon-伪 plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol. 2012;55:58鈥?1. CrossRef
  73. Rallon N, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin 28B gene with response to hepatitis C therapy in HIV/hepatitis C virus coinfected patients. AIDS. 2010;24:F23鈥?. CrossRef
  74. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with pegylated interferon/ribavirin in patients coinfected with chronic HCV and HIV-1: week 24 interim analysis of the TMC435-C212 study. CROI 2013, Atlanta, GA, March 3鈥? 2013. [Abstract 154LB].
  75. Zeuzem S, Soriano V, Asselah T, et al. Interferon-free treatment with faldaprevir and BI-207127 for genotype 1 HCV infection. N Engl J Med. (in press).
  76. Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4: high rates of early virologic response in HCV genotype 1/HIV coinfected patients treated with faldaprevir鈥?鈥塸egylated interferon and ribavirin. CROI 2013, Atlanta, GA, March 3鈥?, 2013. [Abstract 40LB].
  77. Sabo J, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. CROI 2013, Atlanta, GA. March 3鈥?, 2013, [Abstract 35].
  78. Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with NS5B polymerase inhibitors. Exp Opin Pharmacother. (in press).
  79. Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol. 2013;9:5鈥?6. CrossRef
  80. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. (in press).
  81. Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. (in press).
  82. Rodriguez-Torres M, Gonzales Rodriguez J, et al. HIV/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir. ICAAC 2012, Sept 9鈥?2 2012. [Abstract H鈥?921a].
  83. Golitsina N, Danehy F, Fellows R, Cretton-Scott E, Standring D. Evaluation of the role of three candidate human kinases in the conversion of the HCV inhibitor 2鈥?C-methyl-cytidine to its 5鈥?monophosphate metabolite. Antivir Res. 2010;85:470鈥?1. CrossRef
  84. Guedi J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the HCV half-life. Proc Natl Acad Sci U S A. 2013;110:3991鈥?. CrossRef
  85. Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216鈥?4. CrossRef
  86. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. (in press).
  87. Soriano V, Barreiro P, Sherman K. The changing epidemiology of liver disease in HIV patients. AIDS Rev. 2013;15:25鈥?1.
  88. Maida I, N煤帽ez M, R铆os MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177鈥?2. CrossRef
  89. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187鈥?2. CrossRef
  90. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case鈥揷ontrol study. Clin Infect Dis. 2009;49:626鈥?5. CrossRef
  91. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis. 2011;24:12鈥?. CrossRef
  92. Vispo E, Cevik M, Rockstroh J, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis. 2013;56:1117鈥?2. CrossRef
  93. Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV-coinfected patients. HIV Clin Trials. 2008;9:440鈥?. CrossRef
  94. Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained virological response with daclatasvir plus sofosbuvir +/鈭?ribavirin in chronic HCV genotype 1 infected patients who previously failed telaprevir or boceprevir. J Hepatol. 2013;58(Suppl):570. [Abstract 1417].
  95. Ford N, Singh K, Cooke G, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012;54:1465鈥?2. CrossRef
  96. Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Sem Liver Dis. 2012;32:147鈥?7. CrossRef
  97. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML): a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. (in press).
  
• 作者单位：Vincent Soriano (1)
  Eugenia Vispo (1)
  Jose Vicente Fernandez-Montero (1)
  Pablo Labarga (1)
  Pablo Barreiro (1)
  
  1. Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid, 28029, Spain
  

文摘

Liver disease is currently one of the leading causes of hospitalization and death in HIV-positive individuals. Coinfection with the hepatitis C virus (HCV) is a major contributor to this trend. Besides hepatic damage, which is enhanced in the presence of HIV-associated immunosuppression, HCV may contribute to disease in coinfected individuals by potentiating immune activation and chronic inflammation, which ultimately account for an increased risk of cardiovascular events, kidney disease, and cancers in this population. Fortunately, hepatitis C therapeutics has entered a revolutionary era in which we hope that most patients treated with the new oral direct-acting antivirals (DAA) will be cured. However, many challenges preclude envisioning a prompt elimination of HCV from the coinfected population. Issues that should be addressed include the following: (1) rising incidence of acute hepatitis C in men who have sex with men, and expansion/recrudescence of injection drug use in some settings/regions; (2) adverse drug interactions between antiretrovirals and DAA; and (3) high cost of DAA, which may lead many to defer or fail to access appropriate therapy.